vCJD transfusion-associated Fourth Case UK

My Photo
Name:
Location: BACLIFF, Texas, United States

My mother was murdered by what I call corporate and political homicide i.e. FOR PROFIT! she died from a rare phenotype of CJD i.e. the Heidenhain Variant of Creutzfeldt Jakob Disease i.e. sporadic, simply meaning from unknown route and source. I have simply been trying to validate her death DOD 12/14/97 with the truth. There is a route, and there is a source. There are many here in the USA. WE must make CJD and all human TSE, of all age groups 'reportable' Nationally and Internationally, with a written CJD questionnaire asking real questions pertaining to route and source of this agent. Friendly fire has the potential to play a huge role in the continued transmission of this agent via the medical, dental, and surgical arena. We must not flounder any longer. ...TSS

Wednesday, September 19, 2012

Prion reduction of red-blood-cells

INTERNATIONAL FORUM



Prion reduction of red-blood-cells



J. Coste, C. Prowse, C. Grabmer, H. Schennach, P. Santos Prado Scuracchio, S. N. Wendel, M. Germain, G. Delage, T. Krusius, S. Ekblom-Kullberg, P. Tiberghien, J. O’Riordan, W. G. Murphy, Ø. Flesland, M. Turner, L. Williamson, L. Gregori, J. Epstein, D. Asher, S. Panzer, H. W. Reesink



Article first published online: 20 APR 2012



DOI: 10.1111/j.1423-0410.2012.01597.x



© 2012 The Author(s). Vox Sanguinis



© 2012 International Society of Blood Transfusion




J. Coste, C. Prowse, C. Grabmer, H. Schennach, P. Santos Prado Scuracchio, S. N. Wendel, M, Germain, G. Delage, T. Krusius, S. Ekblom-Kullberg. P, Tiberghien, J. O'Riordan, W. G, Murphy, Ø. Flesland, M. Turner, L Williamson, L Gregori, J. Epstein, D. Asher, S. Panzer, H. W. Reesink



First page of article



It is now very likely that the infectious agent responsible for variant Creutzfeldt-Jakob disease (vCJD), a fatal disease of the brain, can he passed from person to person through blood transfusion and that this infectious agent is present in the blood or affected individuals long before clinical signs of the disease become apparent. This has led to major concerns that a pool of such infectious, symptomless indi- viduals could exist and that some of these could be rou- tinely donating blood leading to further cases or transfusion-related person-to-person disease transmission. In the UK to date, four instances of probable transmission of vCJD by blood transfusion have been identified by the UK Transfusion Medicine Epidemiology Review (TMER), including three clinical cases of vCJD and one sub- or pre- clinical infection. Recently, a fifth case of vCJD has been identified with a history of blood transfusion in infancy. The donors who provided the components transfused could not be identified, but a blood donor known to have donated blood to another individual who subsequently developed vCJD could have been a donor to the index case [1]. In February 2009. it was announced that PrPTSE infection was found in the spleen or a 74-year-old neurological asymp- tomatic patient with haemophilia, who had received units of FVIII concentrate prepared from plasma pools known to include donations from a vCJD donor. He had also received 14 units of red cell concentrates (RCCs) [2]. One method of preventing transfusion-related disease transmission would be routinely screening all blood donations for the presence of the infectious agent. Several techniques aim to detect PrPTSE in blood, but none have reached the licensing stage for human use. However, recently, Edgeworth el al. [3] reported a new test to identify vCJD-infected blood. The assay was applied on a coded panel of blood samples. The only samples that were reactive were from patients in clini- cal stage of vCJD. But work is still needed to develop the assay into a screening assay with sufficient sensitivity to detect the presumably lower concentrations that are expected to be present in blood of asymptomatic carriers. A different approach is to reduce prion infectivity from blood and blood components. At present, three companies have developed filters to remove infectious prions from



260



RCCs. The MacoPharma P-Capt Prion Capture, which can be connected to any leucoreduced RCC, is 3 prion-specific filter incorporating PRDT patented ligand technology for the selective adsorption of prions. The P-Capt Filter was CE marked in September 2006. lndependent UK evaluations have been performed in terms of operational use, of quality of filtered components and whether filtration resulted in any changes to blood group antigens [4]. Pall Corporation has CE marked in 2009 a Leukotrap Affinity Prion Reduc- tion Filter System that concurrently reduces leucocytes and infectious prions [5]. Moreover, Asahi/Fenwal and Pall Corporation have developed a New Combination Filter for Prion and Leukoreduction. These filters are not CE marked yet. Finally, manufacturers of pooled plasma and plasma products have been introducing specific steps to remove infectious prion agents from their products [6].



Such a prion removal method may be implemented in some countries on RCCs in the near future, It seemed. there- fore, of interest to collect information by sending the fol- lowing quesuons to expert in the field.



Question 1



Is it likely that a prion removal filter of RCCs will be imple- mented in your country/centre?



(a) If so, will it concern all RCC or RCCs for only certain groups of patients



(b) How many filtered RCCs have been transfused and what was the experience?



(c) Have you noticed any untoward reactions or effects that were going to the filtration process?



(d) If the product is less potent (e.g. less haemoglobin con- tent) as a result of processing is this of any concern



Question 2



If a prion removal device of RCCs will probably not be implemented in your country/centre. what ale the reasons for this decision?



(a) Are there still doubts about the efficacy and the safety



(b) Is it an economic question?



(c) Is it because no vCJD cases have been notified in your country?








Wednesday, September 12, 2012


Blood test closer for mad cow disease, Alzheimers and Parkinson's








Monday, August 13, 2012


Summary results of the second national survey of abnormal prion prevalence in archived appendix specimens August 2012








Thursday, August 16, 2012


Blood products, collected from a donor who was at risk for variant Creutzfeldt-Jakob disease ( vCJD) USA JUNE, JULY, AUGUST 2012








Monday, June 11, 2012


Guidance for Industry Draft Guidance for Industry: Amendment to “Guidance for Industry: Revised Preventive Measures to Reduce the Possible Risk of Transmission of Creutzfeldt-Jakob Disease and Variant Creutzfeldt-Jakob Disease by Blood and Blood Products”








Friday, June 29, 2012


Highly Efficient Prion Transmission by Blood Transfusion








Sunday, June 3, 2012


A new neurological disease in primates inoculated with prion-infected blood or blood components








Monday, July 23, 2012


The National Prion Disease Pathology Surveillance Center July 2012
























TSS

Thursday, September 06, 2012

HANSARD, vCJD, blood, FFP, 5 Sep 2012 : Column 353W SaBTO

HANSARD, vCJD, blood, FFP, 5 Sep 2012 : Column 353W SaBTO




5 Sep 2012 : Column 353W




Health Blood: Contamination Sir Paul Beresford: To ask the Secretary of State for Health (1) pursuant to the answer of 14 May 2012, Official Report, column 26W, on blood: contamination; for what reason the Advisory Committee on the Safety of Blood, Tissues and Organs, reversed its 2009 recommendation on the importation of Fresh Frozen Plasma although the risk of transmitted variant Creutzfeldt-Jacob Disease by blood remains unchanged; and if he will make a statement; [119254]




(2) with reference to the minutes of the Advisory Committee on the Safety of Blood, Tissues and Organs meeting of 9 March 2012, to what extent cost-effectiveness is used to inform Government policy on public health safety measures on (a) blood safety and (b) variant Creutzfeldt-Jacob Disease; [119255]




(3) if he will publish the data his Department used to inform its decision to accept the recommendation of the Advisory Committee on the Safety of Blood, Tissues and Organs on Fresh Frozen Plasma of 9 March 2012; and if he will make a statement; [119256]




5 Sep 2012 : Column 362W




(4) for what reason the data his Department used to inform its decision on the importation of fresh frozen plasma is not publicly available; [119257]




(5) what the names are of the companies his Department and its relevant committees approached to (a) inform their thinking on extending importation of fresh frozen plasma and (b) estimate the cost of extending importation of fresh frozen plasma; and when each company was approached. [119258]




Dr Poulter: On making the March 2012 decision on the importation of fresh frozen plasma, the independent scientific Advisory Committee on the Safety of Blood, Tissues and Organs (SaBTO) considered all the available evidence including safety, efficacy and cost-effectiveness. SaBTO concluded that there should be no extension of the importation of fresh frozen plasma (FFP) to patients beyond those for whom it is already recommended (high-usage adult patients, and those aged 16 and under (i.e. born since 1996), who are unlikely to have been exposed to BSE through diet). SaBTO's terms of reference require consideration of cost-effectiveness evidence when making recommendations. A key consideration is the number of potential future clinical vCJD cases that might be caused by transfusion of FFP in the absence of any extension to importation. Given the continuing scientific uncertainties, a precautionary approach remains justified, and a wide range of scenarios have been considered. Nevertheless, the continuing absence to date of any known clinical cases attributable to FFP transfusion restricts the range of future possibilities, and the cost-effectiveness calculations used by SaBTO reflect this point.




Information used by SaBTO in making their recommendation is publicly available, redacted in accordance with freedom of information principles, at:








A copy has also been placed in the Library.


Details that could provide commercial information are not included for reasons of commercial confidentiality.









Friday, May 11, 2012


ProMetic Life Sciences Inc.: P-Capt® Filtration Prevents Transmission of Endogenous Blood-Borne Infectivity in Primates







Wednesday, May 9, 2012


Detection of Prion Protein Particles in Blood Plasma of Scrapie Infected Sheep







Wednesday, February 1, 2012


CJD and PLASMA / URINE PRODUCTS EMA Position Statements Alberto Ganan Jimenez, European Medicines Agency PDA TSE Safety Forum, 30 June 2011







ENFORCEMENT REPORT


Enforcement Report - Week of August 29, 2012


Class II, Blood products, collected from a donor who was at risk for variant Creutzfeldt-Jakob Disease (vCJD), were distributed. Belle Bonfils Memorial Blood ...







Thursday, August 16, 2012


Blood products, collected from a donor who was at risk for variant Creutzfeldt-Jakob disease ( vCJD) USA JUNE, JULY, AUGUST 2012







Sunday, June 3, 2012


A new neurological disease in primates inoculated with prion-infected blood or blood components







Friday, June 29, 2012


Highly Efficient Prion Transmission by Blood Transfusion







Thursday, August 16, 2012


Blood products, collected from a donor who was at risk for variant Creutzfeldt-Jakob disease ( vCJD) USA JUNE, JULY, AUGUST 2012







price of prion poker goes up again $$$





Monday, June 11, 2012


Guidance for Industry Draft Guidance for Industry: Amendment to “Guidance for Industry: Revised Preventive Measures to Reduce the Possible Risk of Transmission of Creutzfeldt-Jakob Disease and Variant Creutzfeldt-Jakob Disease by Blood and Blood Products”







Saturday, August 18, 2012


RedCross Request Jerome H. Holland Laboratory is collecting small volumes of blood from patients afflicted with various forms of transmissible spongiform encephalopathies (TSE)/prion diseases and their blood-related family members 2012







Monday, August 13, 2012


Summary results of the second national survey of abnormal prion prevalence in archived appendix specimens August 2012







Friday, August 24, 2012


Iatrogenic prion diseases in humans: an update








TSS